Tenapanor hydrochloride - Generic Drug Details

What are the generic sources for tenapanor hydrochloride and what is the scope of patent protection?

Tenapanor hydrochloride is the generic ingredient in two branded drugs marketed by Ardelyx Inc and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tenapanor hydrochloride has one hundred and five patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for tenapanor hydrochloride

International Patents:	105
US Patents:	8
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	23
Patent Applications:	15
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tenapanor hydrochloride
What excipients (inactive ingredients) are in tenapanor hydrochloride?	tenapanor hydrochloride excipients list
DailyMed Link:	tenapanor hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tenapanor hydrochloride

Dosage:

TABLET;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tenapanor hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ardelyx	PHASE3
Massachusetts General Hospital	PHASE3
Cedar Valley Digestive Health Center	PHASE2

See all tenapanor hydrochloride clinical trials

Pharmacology for tenapanor hydrochloride

Drug Class	Sodium-Hydrogen Exchanger 3 Inhibitor
Mechanism of Action	Organic Anion Transporting Polypeptide 2B1 Inhibitors Sodium-Hydrogen Exchanger 3 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for tenapanor hydrochloride

A06AX	Other drugs for constipation
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

US Patents and Regulatory Information for tenapanor hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No			Y

International Patents for tenapanor hydrochloride

Country	Patent Number	Title	Estimated Expiration
Argentina	095852
Australia	2014250956
Australia	2019204676
Brazil	112015025805
Canada	2909169
China	105392483

Tenapanor Hydrochloride Market Dynamics and Financial Trajectory: Revenue Build, Exclusivity Timelines, Competitive Set, and Generic/Biosimilar Risk

Last updated: July 5, 2026

Tenapanor hydrochloride (constipation/IBS-C program) is commercially driven by IBS-C and payer coverage dynamics, with financial trajectory tied to NBRx and prescription persistence, specialty pharmacy mix, and the pace of formulary adoption versus liquidation risk from competing agents. A full, decision-grade financial outlook requires drug-level revenue and U.S. launch/exclusivity facts.

Because those inputs (tenapanor-specific revenue by geography and payer channel; Orange Book exclusivities; Orange Book patent lists; FDA regulatory and launch milestones; and current generic litigation posture) are not provided in the prompt, a complete and accurate market-and-financial trajectory cannot be produced under the operating constraints.

How does tenapanor hydrochloride make money in IBS-C: revenue drivers and payer coverage mechanics?

Featured snippet answer: Tenapanor’s commercial performance is primarily determined by IBS-C patient volume onboarding, continuity of therapy, and formulary placement across Medicare, Medicaid, and commercial plans, with net pricing shaped by pharmacy benefit manager (PBM) contracting and specialty pharmacy distribution economics.

What are the key demand levers for tenapanor in IBS-C?

• Prescriber adoption: gastroenterology and primary care initiation behavior.
• Patient persistence: discontinuation rates versus alternative constipation and gut-brain axis agents.
• Formulary dynamics: tier placement and prior authorization (PA) outcomes.
• Supply and access: distribution network and reimbursement friction.
• Differentiation versus older constipaton agents: response rate and tolerability in real-world settings.

What are the key reimbursement mechanics that shape net sales?

• Contracted net price: rebate and performance-based components with major PBMs.
• Coverage restrictions: step edits and PA criteria tied to symptom history.
• Benefit design: preferred tier positioning versus competing GI symptom therapies.
• Pharmacy channel: specialty versus retail mix affects economics and fulfillment costs.

When does tenapanor hydrochloride lose exclusivity: patent and exclusivity timeline to generic entry risk?

Featured snippet answer: Exclusivity and patent expiry timing is the gating variable for generic entry. Without the Orange Book listing and patent term details for tenapanor hydrochloride, a correct timeline and entry-risk window cannot be stated.

What exclusivity can delay generic competition?

• Hatch-Waxman regulatory exclusivities (if applicable): new chemical entity (NCE), new clinical investigations, pediatric exclusivity.
• Orange Book patent coverage: composition, formulation, and method-of-use claims.

What is the generic entry risk profile?

• Paragraph IV challenges: timing depends on the first 30-month stay and the probability of injunction or settlement.
• Launch timing sensitivity: disputes over claim scope and product design changes.
• Payer switching: even after generic availability, net price erosion depends on formulary behavior.

What patents protect tenapanor hydrochloride: composition, formulation, and method-of-use coverage?

Featured snippet answer: Patent coverage is typically split across active ingredient/formulation and method-of-use claims. A verified count, claim types, assignees, and expiration dates require the Orange Book patent list for tenapanor hydrochloride.

Patent estate categories that typically matter for strategy

• Composition-of-matter: covers active ingredient or salt forms (tenapanor hydrochloride).
• Formulation: tablets, film coatings, particle size, excipient systems, and release characteristics.
• Method-of-use: IBS-C dosing regimens and patient selection.
• Manufacturing: scale-up process claims that can block early supply.

Which jurisdictions matter for exclusivity and litigation?

• U.S. FDA Orange Book patents govern generic entry risk in the U.S.
• International filings matter for commercial competition, but not for U.S. ANDA timing.

How many generic companies can enter tenapanor hydrochloride and what would that do to price?

Featured snippet answer: The number of entrants determines the pace and depth of price erosion, but the forecast cannot be quantified without confirmed ANDA/ANDA-case data or at least the number of Paragraph IV filings.

Price erosion drivers after generic launch

• Number of approved ANDAs and authorized generics.
• Manufacturer capacity and supply stability.
• PBM tiering behavior and automatic substitution policies.
• Switch costs for prescribers and patients.

How fast does net revenue typically decline after first generic?

• First-year erosion often depends on formulary switching speed and PA enforcement.
• Subsequent entrants determine whether price erosion stabilizes or continues.

What is the current competitive landscape for tenapanor hydrochloride in IBS-C?

Featured snippet answer: Competitive pressure in IBS-C comes from a mix of newer gut-brain and intestinal secretion agents plus established constipation therapies. Relative performance depends on response rates, tolerability, and plan coverage, not mechanism alone.

Who competes against tenapanor in IBS-C?

• Prescription constipation and IBS-C agents with overlapping endpoints (stool frequency and abdominal pain symptom improvement).
• Gastroenterology-focused brands with strong formulary relationships.

How do payers compare these agents?

• Trial design endpoints: whether the payer contracts on “responder” criteria.
• Safety/tolerability profiles: diarrhea incidence or constipation rebound can change PA policies.
• Real-world persistence: therapies that retain patients after initial fills typically win formulary share.

What is the FDA status of tenapanor hydrochloride and which pathway governs access?

Featured snippet answer: FDA approval and label scope govern use and reimbursement, including restrictions such as adult indication boundaries and dosing instructions. A correct status summary requires FDA review history and label details.

What label scope changes market dynamics?

• Indication breadth: IBS-C versus broader chronic constipation.
• Dosing schedule: adherence and persistence effects.
• Contraindications and warnings: patient mix impact.

What tenapanor hydrochloride litigation affects generic entry: Paragraph IV cases and settlements?

Featured snippet answer: Litigation affects entry through 30-month stays, injunction threats, and settlement-driven launch dates. Case names, filing dates, and settlement terms are required for an accurate risk assessment.

What metrics decide the litigation outcome?

• Claim strength: breadth of composition and method-of-use claims.
• Infringement risk: generic design-around feasibility.
• Litigation posture: district court rulings and appeal status.
• Settlement structure: “carve-out” scopes and stipulated launch dates.

How does tenapanor hydrochloride compare with linaclotide, plecanatide, lubiprostone, and tegaserod class alternatives in adoption economics?

Featured snippet answer: Comparative adoption is driven by net price and formulary placement, then reinforced by persistence and patient satisfaction, not by mechanism similarity.

What drives comparative value to health plans?

• Total cost of therapy: acquisition plus administration and monitoring.
• Adherence and outcomes: reductions in rescue medication use.
• Safety events that trigger discontinuations and rework.

What drives comparative value to prescribers?

• Predictable onset and tolerability.
• Simple dosing and minimal drug-drug interactions.
• Confidence in long-term adherence patterns.

How strong is the patent estate for tenapanor hydrochloride: litigation durability and design-around barriers?

Featured snippet answer: Patent strength must be evaluated by claim scope, prosecution history, and litigation history. A defensible score cannot be produced without the Orange Book list and known court outcomes.

What would indicate stronger estate durability?

• Multiple independently enforceable claim types (composition + formulation + method-of-use).
• Broad claim language that limits design-around.
• Prior unfavorable novelty or obviousness determinations.

What would indicate weaker estate durability?

• Narrow formulation or method claims tied to specific dosing schedules.
• Weak evidence of inventive step for formulation/manufacturing.
• Patent portfolio concentration into a single expiration year.

What generic entry risks exist for tenapanor hydrochloride in the U.S.: timing and pathway scenarios?

Featured snippet answer: Generic entry timing depends on ANDA filing dates, 30-month stay triggers, and whether infringement is upheld. Timing scenarios cannot be enumerated without ANDA and Orange Book facts.

Scenario framework that must be populated with confirmed data

• Scenario A: First Paragraph IV filing triggers a 30-month stay; settlement sets an agreed launch date.
• Scenario B: Litigation ends in favor of brand; generic launch delayed until later expiration.
• Scenario C: Partial invalidation narrows claim coverage; launch proceeds with design-around product.

Key takeaways

• Tenapanor hydrochloride’s financial trajectory is primarily a function of IBS-C demand capture, persistence, and payer formulary adoption.
• Generic and biosimilar risk is governed by U.S. Orange Book exclusivity and patent coverage, plus ANDA/Paragraph IV litigation outcomes.
• A complete, decision-grade market and financial trajectory cannot be stated without verified tenapanor-specific Orange Book listings, FDA label/regulatory milestones, and commercial/revenue performance data.

FAQs

1. Does tenapanor hydrochloride face earlier generic entry from formulation design-arounds or only from composition claims?
2. How do prior authorization and step-edit requirements typically change IBS-C drug net pricing?
3. What endpoints do payers and formularies use to contract IBS-C therapies, and how does that impact uptake?
4. What settlement terms most commonly determine the effective launch date for an ANDA challenger?
5. How does competition affect net sales through switching versus incremental category growth in IBS-C?

References

1. No sources were provided in the prompt, and no external, tenapanor-specific data can be cited.